Abstract
Uterine serous carcinoma (USC) is a highly aggressive variant of endometrial cancer. Although it only represents less than 10% of all cases, it accounts for a disproportionate number of deaths from endometrial cancer. Comprehensive surgical staging followed by carboplatin and paclitaxel chemotherapy represents the mainstay of USC therapy. Vaginal cuff brachytherapy is also of potential benefit in USC. Recent whole-exome sequencing studies have demonstrated gain of function of the HER2/NEU gene, as well as driver mutations in the PIK3CA/AKT/mTOR and cyclin E/FBXW7 oncogenic pathways in a large number of USCs. These results emphasize the relevance of these novel therapeutic targets for biologic therapy of chemotherapy-resistant recurrent USC.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Class I Phosphatidylinositol 3-Kinases
-
Cyclin E / drug effects
-
Cyclin E / genetics
-
Cystadenocarcinoma, Serous / drug therapy*
-
Cystadenocarcinoma, Serous / genetics
-
Cystadenocarcinoma, Serous / pathology
-
Drug Resistance, Neoplasm / drug effects
-
Female
-
Genes, erbB-2 / drug effects
-
Genes, erbB-2 / genetics
-
Humans
-
Molecular Targeted Therapy / methods*
-
Mutation
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / genetics
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm Staging
-
Phosphatidylinositol 3-Kinases / drug effects
-
Phosphatidylinositol 3-Kinases / genetics
-
Randomized Controlled Trials as Topic
-
Uterine Neoplasms / drug therapy*
-
Uterine Neoplasms / genetics
-
Uterine Neoplasms / pathology
Substances
-
Antineoplastic Agents
-
Cyclin E
-
Phosphatidylinositol 3-Kinases
-
Class I Phosphatidylinositol 3-Kinases
-
PIK3CA protein, human